Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. DFTX
10. IBM

Go back to Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology

Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf

December 7, 2020 6:35 AM EST

BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to collaborate with the National Institute of Allergy and Infectious Diseases (NIAID),... More